GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Liabilities-to-Assets

Infant Bacterial Therapeutics AB (OSTO:IBT B) Liabilities-to-Assets : 0.26 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Infant Bacterial Therapeutics AB's Total Liabilities for the quarter that ended in Mar. 2025 was kr54.39 Mil. Infant Bacterial Therapeutics AB's Total Assets for the quarter that ended in Mar. 2025 was kr207.92 Mil. Therefore, Infant Bacterial Therapeutics AB's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2025 was 0.26.


Infant Bacterial Therapeutics AB Liabilities-to-Assets Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Liabilities-to-Assets Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.05 0.13 0.29

Infant Bacterial Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.20 0.15 0.29 0.26

Competitive Comparison of Infant Bacterial Therapeutics AB's Liabilities-to-Assets

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Liabilities-to-Assets falls into.


;
;

Infant Bacterial Therapeutics AB Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Infant Bacterial Therapeutics AB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=69.303/239.566
=0.29

Infant Bacterial Therapeutics AB's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2025 is calculated as

Liabilities-to-Assets (Q: Mar. 2025 )=Total Liabilities/Total Assets
=54.392/207.916
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infant Bacterial Therapeutics AB  (OSTO:IBT B) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Infant Bacterial Therapeutics AB Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines